ASXL2 and familial pancreatic carcinoma: As the first study concentrating on ASXL2 and pancreatic cancer, our work suggested that ASXL2 expression is correlated with the OS among PAAD patients, several tumor-infiltrating immune cells, and the possible response to chemotherapy and immunotherapy, which highlight the prognostic and predictive value of ASXL2 in pancreatic cancer.